Fatty liver disease (MASLD/MASH) trials in Italy

In Italy 33 Also abroad 367

33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Bologna, Florence, Milan, Padova, Palermo, Rome
Age
18 years to 75 years
People
360 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07631637 · EU 2026-525916-33-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Bologna, Foggia, Messina, Milan, Modena, Naples, Novara, Roma, Rozzano, San Giovanni Rotondo, Torino
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Bologna, Foggia, Milan, Modena, Novara, Palermo, Rome, Rozzano, San Giovanni Rotondo, Turin, Verona
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Bologna, Foggia, Milan, Modena, Palermo, Rome, Rozzano, San Giovanni Rotondo, Turin
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Bologna, Catania, Foggia, Messina, Milan, Modena, Novara, Rome, Rozzano, San Giovanni Rotondo, Turin
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Bergamo, Foggia, Milan, Modena, Naples, Novara, Palermo, Rome, Rozzano, Turin
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Bergamo, Foggia, Milan, Novara, Palermo, Rome, Rozzano, Turin
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Not yet taking people in Italy
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Bergamo, Bologna, Foggia, Milan, Padova, Rome, Rozzano
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Italy
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Bergamo, Bologna, Foggia, Milan, Padova, Rome, Rozzano
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Bologna, Catania, Foggia, Messina, Milan, Modena, Novara, Roma, Rozzano, San Giovanni Rotondo, Torino
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma, Rome, Rozzano, Torino, Verona
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
No phaseTaking people
Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
Where
Rome
Age
18 years and over
People
252
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06879236
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Ancona, Bergamo, Bologna, Florence, Foggia, Milan, Padova, Rome, Rozzano, Turin
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
Phase 4Taking people
Fibrosis Lessens After Metabolic Surgery
Where
Milan, Roma
Age
18 years to 75 years
People
120 worldwide
Run by
The Cleveland Clinic
See details and how to joinNCT06374875
No phaseNot yet taking people in Italy
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
Where
Castellana Grotte
Age
18 years and over
People
24
Run by
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
See details and how to joinNCT07644936
No phaseTaking people
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
Where
Roma
Age
18 years and over
People
450 worldwide
Run by
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
See details and how to joinNCT07652151
No phaseTaking people
EVOO and Metabolic Liver Health in MASLD
Where
Castellana Grotte
Age
18 years to 65 years
People
60
Run by
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
See details and how to joinNCT07412444
No phaseTaking people
Liver Steatosis in Pediatric CD Patients
Where
Palermo
Age
1 year to 14 years
People
91
Run by
University of Palermo
See details and how to joinNCT06206616
No phaseTaking people
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
Where
Castellana Grotte
Age
18 years to 65 years
People
90
Run by
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
See details and how to joinNCT06186869
No phaseTaking people
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Where
Rome
Age
18 years and over
People
500
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07440511
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Bologna, Foggia, Messina, Milan, Modena, Naples, Novara, Pisa, Rome, Rozzano, San Giovanni Rotondo, Turin
Age
18 years and over
People
244 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00
No phaseTaking people
Evaluation of Risk of hEpatocellular Carcinoma
Where
Milan
Age
45 years to 75 years
People
500
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06523179
No phaseTaking people
Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)
Where
Milan
Age
18 years and over
People
60
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06856252
No phaseTaking people
The Liver BIoBank Lombardia of Fatty Liver
Where
Milan
Age
40 years to 60 years
People
2,500
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT06566105
No phaseNot yet taking people in Italy
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
Where
Turin
Age
18 years and over
People
30,000 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT06907563